Proteomics of human breast ductal carcinoma in Situ

Cancer Research

Volumn 62, Issue 22, 2002, Pages 6740-6749

  Wulfkuhle, Julia D ^a   Sgroi, Dennis C ^b   Krutzsch, Henry ^a   McLean, Kelley ^a,g   McGarvey, Kelly ^a   Knowlton, Melodie ^a   Chen, She ^c   Shu, Hongjun ^c   Sahin, Aysegul ^d   Kurek, Raffael ^e   Wallwiener, Diethelm ^e   Merino, Maria J ^a   Petricoin, Emanuel F ^f   Zhao, Yingming ^c,g   Steeg, Patricia S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CARCINOMA IN SITU; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PROTEOMICS;

EID: 0037112454     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Skinner, K., and Silverstein, M. The management of ductal carcinoma in situ of the breast. Endocr. Relat. Cancer, 8: 33-45, 2001
2. Ernster, V., Barclay, J., Kerlikowske, K., Grady, D., and Henderson, I. Incidence of and treatment for ductal carcinoma in situ of the breast. J. Am. Med. Assoc., 275: 913-918, 1996
3. Lagios, M. Heterogeneity of duct carcinoma in situ (DCIS): Relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Lett., 90: 97-102, 1995
4. Page, D., DuPont, W., Rogers, L., and Landenberger, M. Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer (Phila.), 49: 751-758, 1982
5. Silverstein, M., Lagios, M., Groshen, S., Waisman, J., Lewinsky, B., Martino, S., Gamagami, P., and Colbum, W. The influence of margin width on local control of ductal carcinoma in situ of the breast. N. Engl. J. Med., 340: 1455-1461, 1999
6. Ottesen, G., Graversen, H., Blichert-Toft, M., Christensen, I., and Andersen, J. Carcinoma in situ of the female breast, 10 year follow-up results of a prospective nationwide study. Breast Cancer Res. Treat., 62: 197-210, 2000
7. Mirza, N., Vlastos, G., Meric, F., Sahin, A., Singletary, S., Newman, L., Kuerer, H., Ames, F., Ross, M., Feig, B., Pollock, R., Buchholz, T., NcNeese, M., Strom, E., Hortobagyi, G., and Hunt, K. Ductal carcinoma-in-situ: Long-term results of breast-conserving surgery. Ann. Surg. Oncol., 7: 656-664, 2000
8. Bijker, N., Petersen, J., Duchateau, L., Julien, J., Fentiman, I., Duval, C., Di Palma, S., Simony-Lafontaine, J., de Mascarel, I., and van de Vijver, M. J. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma in situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol., 19: 2263-2271, 2001
9. Ringbcrg, A., Anagnostake, L., Anderson, H., Idvall, I., and Ferno, M. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast: Relationship to ipsilateral local recurrence and histopathological characteristics. Eur. J. Cancer. 37: 1514-1522, 2001
10. Boyages, J., Delaney, G., and Taylor, R. Predictors of local recurrence after treatment of ductal carcinoma in situ. Cancer (Phila.), 85: 616-628, 1999
11. Habel, L., Daling, J., Newcomb, P., Self, S., Porter, P., Stanford, J., Seidel, K., and Weiss, N. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol. Biomark. Prev., 7: 689-696, 1998
12. Badve, S., A’Hern, R., Ward, A., Mills, R., Pinder, S., Ellis, I., Gusterson, B., and Sloane, J. Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. Hum. Pathol., 29: 915-923, 1998
13. O’Connell, P., Pekkel, V., Fuqua, S., Osborne, C., Clarke, G., and Alfred, D. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J. Natl. Cancer Inst. (Bethesda), 90: 697-703, 1998
14. Buerger, H., Otterbach, F., Simon, R., Poremba, C., Diallo, R., Decker, T., Reithdorf, L., Brinkschmidt, C., Dodkhom-Dwomiczak, B., and Boecker, W. Comparative genomic hybridization of ductal carcinoma in situ of the breast: Evidence of multiple genetic pathways. J. Pathol., 187: 396-402, 1999
15. Waldman, F. M., DeVries, S., Chew, K. L., Moore, D. H., II. Kerlokowske, K., and Ljung, B. M. Chromosomal alteration in ductal carcinoma in situ and their in situ recurrences. J. Natl. Cancer Inst. (Bethesda), 92: 313-320, 2000
16. Ottesen, G., Christensen, I., Larsen, J., Larsen, J., Baldetorp, B., Linden, T., Hansen, B., and Andersen, J. Carcinoma in situ of the breast: Correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res. Treat., 60: 219-226, 2000
17. Shpitz, B., Zimlichman, S., Zemer, R., Bornstein, Y., Zehavi, T., Liverant, S., Bernehaim, J., Kaufman, Z., Klien, E., Shapira, Y., and Klein, A. Telomerase activity in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat., 58: 65-66, 1999
18. Claus, E., Chu, P., Howe, C., Davison, T., Stern, D., Carter, D., and DiGiovanna, M. Patholobiologic findings in DCIS of the breast: Morphologic features, angiogenesis, Her-2/neu and hormone receptors. Exp. Mol. Pathol., 70: 303-316, 2001
19. Siziopikou, K., Prioleau, J., Harris, J., and Schnitt, S. Bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer (Phila.), 77: 499-506, 1996
20. Gobbi, H., Arteaga, C., Jensen, R., Simpson, J., DuPont, W., Olson, S., Schuyler, P., Plummer, W. D., Jr., and Page, D. Loss of expression of transforming growth factor b type II receptor correlates with high tumour grade in human breast in situ and invasive carcinomas. Histopathology, 36: 168-177, 2000
21. Weinstat-Saslow, D., Merino, M. J., Manrow, R. E., Lawrence, J. A., Bluth, R. F., Wittenbel, K. D., Simpson, J. F., Page, D. L., and Steeg, P. S. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med., 1: 1257-1260, 1995
22. Lawrence, J., Merino, M., Simpson, J., Manrow, R., Page, D., and Steeg, P. A high risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor. Cancer Epidemiol. Biomark. Prev., 7: 29-35, 1998
23. Guidi, A., Schnitt, S., Fischer, L., Tognazzi, K., Harris, J., Dvorak, H., and Brown, L. Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (Phila.), 80: 1945-1953, 1997
24. Guidi, A., Fischer, L., Harris, J., and Schnitt, S. Microvessel density and distribution in ductal carcinoma insitu of the breast. J. Natl Cancer Inst. (Bethesda), 86: 614-619, 1994
25. Engels, K., Fox, S., Whitehouse, R., Gatter, K., and Harris, A. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J. Pathol., 181: 207-212, 1997
26. Allred, D. C., Clark, G. M., Molina, R., Tandon, A. K., Schnitt, S. J., Gilchrist, K. W., Osborne, C. K., Tormey, D. C., and McGuire, W. L. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol., 23: 974-979, 1992
27. Mommers, E., vanDiest, P., Leonhart, A., Meijer, C., and Baak, J. Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res. Treat., 58: 163-169, 1999
28. Walker, R., Dearing, S., Lane, D., and Varley, J. Expression of p53 protein in infiltrating and in situ breast carcinomas. J. Pathol., 165: 203-211, 1991
29. Lodato, R., Maguire, H., Greene, M., Weiner, D., and LiVolsi, V. Immunohistochemical evaluation of c-erb-B-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod. Pathol., 3: 449-454, 1990
30. Suo, Z., Bjaamer, A., Ottestad, L., and Nesland, J. Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast. Ultrastruct. Pathol., 25: 349-356, 2001
31. Luzzi, V., Holtschlag, V., and Wilson, M. Expression profiling of ductal carcinoma in situ by laser capture microdissection and high density oligonucleotide arrays. Am. J. Pathol., 158: 2005-2010, 2001
32. Porter, D., Krop, I., Nasser, S., Sgroi, D., Kaelin, C., Marks, J., Riggins, G., and Polyak, K. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res., 61: 5697-5702, 2001
33. Hanash, S. Global profiling of gene expression in cancer using genomics and proteomics. Curr. Opin. Mol. Ther., 3: 538-545, 2001
34. Hondermarck, H., Vercoutter-Edouart, A., Revillion, F., Lemoine, J., El-Yazidi-Belkoura, I., Nurcombe, V., and Peryat, J. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics, 1: 1216-1232, 2001
35. Wulfkuhle, J., McLean, K., Pawletz, C., Sgroi, D., Trock, B., Steeg, P., and Petricoin, E. New approaches to proteomic analysis of breast cancer. Proteomics, 1: 1205-1215, 2001
36. Harrington, M., Guderman, D., Zavert, T., Yun, M., and Hood, L. Analytical: micropreparative two-dimensional electrophoresis of proteins. Methods: A Companion to Methods Enzymol., 3: 98-108, 1991
37. Ahram, M., Best, C., Flaig, M., Gillespie, J., Leiva I., Chuaqui, R., Zhou, G., Shu, H., Duray, P., Linehan, W., Raffeld, M., Ornstein, D., Zhao, Y., Petricoin, E. F., III, and Emmert-Buck, M. Proteomic analysis of human prostate cancer. Mol. Carcinog., 33: 9-15, 2002
38. Judson, P., Watson, J., Gehrig, P., Fowler, W. C., Jr., and Haskill, J. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: Possible explanation for failure of combination therapy. Cancer Res., 59: 2425-2432, 1999
39. Tulk, B., and Edwards, J. NCC27, a homolog of intracellular Cl- channel p64, is expressed in brush border of renal proximal tubule. Am. J. Physiol., 274: F1140-F1149, 1998
40. Kang, S., Chae, H., Seo, M., Kim, K., Banes, I., and Rhee, S. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor α. J. Biol. Chem., 273: 6297-6302, 1998
41. Zhang, J., Kim, S., Helmke, B., Yu, W., Du, K., Lu, M., Strobeck, M., Yu, Q., and Parmacek, M. Analysis of SM22a-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol. Cell. Biol., 21: 1336-1344, 2001
42. Adami, H., Malker, B., Holmberg, L., Persson, I., and Stone, B. The relation between survival and age at diagnosis in breast cancer. N. Engl. J. Med., 315: 559-563, 1986
43. Szelei-Stevens, K., Kuske, R., Yantsos, V., Cederbom, G., Bolton, J., and Fineberg, B. The influence of young age and positive family history of breast cancer on the prognosis of ductal carcinoma in situ treated by excision with or without radiation therapy or by mastectomy. Int. J. Radiat. Oncol. Biol. Phys. 48: 943-949, 2000
44. Gajdos, C., Tartter, P., Bleiweiss, I., Bodian, C., and Brower, S. Stage 0 to Stage III breast cancer in young women. J. Am. Coll. Surg., 190: 509-515, 2000
45. Storm, F., Gilchrist, K., Warner, T., and Mahvi, D. Distribution of HSP-27 and Her-2/neu in in situ and invasive ductal breast carcinomas. Ann. Surg. Oncol., 2: 43-48, 1995
46. Fernandez, P., Tabbara, S., Jacobs, L., Manning, F., Tsangaris, T., Schwartz, A., Kennedy, K., and Patierno, S. Overexpression of the glucose-related stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res. Treat., 59: 15-26, 2000
47. Lah, T., Kalman, E., Najjar, D., Gorodetsky, E., Brennan, P., Sommers, R., and Daskal, I. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis. Hum. Pathol., 31:149-160, 2000
48. Fisher, B., Constantino, J., Wickerham, D., Redmmond, C., Kavanah, M., Cronin, W., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieland, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998
49. Fisher, B., Digman, J., and Wolmark, N. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet, 353: 1993-2000, 1999
50. Jordan, V., Gapstur, S., and Morrow, M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J. Natl. Cancer Inst. (Bethesda), 93: 1449-1457, 2001
51. Brown, P., and Lippman, S. Chemoprevention of breast cancer. Breast Cancer Res. Treat., 62: 1-17, 2000
52. Loisel, T., Boujemaa, R., Pantaloni, D., and Carliern, M. Reconstitution of actin-based motility of Listeria and Shigella using pure proteins. Nature (Lond.), 401: 613-616, 1999
53. Zjang, J., Rudra Ganguly, N., Powell, W., and Roy-Burman, P. Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin. Am. J. Pathol., 155: 115-122, 1999
54. Sun, H., Kwiatkiwska, K., Wooten, D., and Yin, H. Effects of CapG overexpression on agonist-induced motility and second messenger generation. J. Cell Biol., 129: 147-156, 1995
55. Janke, J., Schluter, K., Jandrig, B., Theile, M., Kolble, K., Arnold, W., Grinstn, E., Schwatz, A., Estevez-Schwarz, L., Schlag, P., Jockusch, B., and Scherneck, S. Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin I. J. Exp. Med., 191: 1675-1685, 2000
56. Ridley, A. Rho proteins: Linking signaling with membrane trafficking. Traffic, 2: 303-310, 2001
57. Sloane, B., Moin, K., Sameni, M., Tait, L., Rozhin, J., and Ziegler, G. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J. Cell Sci., 107: 373-384, 1994
58. Wilcke, M., Johannes, L., Galli, T., Mayau, V., Goud, B., and Salamero, J. Rab11 regulates the compartmentalization of early endosomes required for efficient transport from early endosomes to the trans-Golgi network. J. Cell Biol., 151: 1207-1220, 2000
59. Chen, W., Feng, Y., Chen, D., and Wandinger-Ness, A. Rab11 is required for trans-Golgi network-to-plasma membrane transport and a preferential target for GDP dissociation inhibitor. Mol. Biol. Cel. 9: 3241-3257, 1998
60. Lippman, M., Dickson, R., Bates, S., Knabbe, C., Huff, K., Swain, S., McManaway, M., Bronzert, D., Kasid, A., and Gelmann, E. Autocrine and paracrine growth-regulation of human breast cancer. Breast Cancer Res. Treat., 7: 59-70, 1986
61. DeGroot, N., Van Kuik-Romeijn, P., Lee, S., and DeBoer, H. Increased immunoglobulin A levels in milk by overexpressing the murine polymeric immunoglobulin receptor gene in the mammary gland epithelial cells of transgenic mice. Immunology, 101: 218-224, 2000
62. Hansen, R., Parra, I., Hilsenbeck, S., Himelstein, B., and Fuqua, S. HSP27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase Yes. Biochem. Biophys. Res. Commun., 282: 186-193, 2001
63. Caruso, J., Laird, D., and Batist, G. Role of HSP90 in mediating cross-talk between the estrogen receptor and the Ah receptor signal transduction pathways. Biochem. Pharmacol., 58: 1395-1403, 1999
64. Daniels, K., Boldt, H., Martin, J., Gardner, L., Meyer, M., and Folberg, R. Expression of type VI collagen in uveal melanomas: Its role in pattern formation and tumor progression. Lab. Investig., 75: 55-66, 1996
65. Lanzafame, S., Magro, G., and Colombatti, A. Expression and distribution of type VI collagen in gynecomastia. Acta Histochem., 96: 219-223, 1994
66. Berggren, M., Husbeck, B., Samulitis, B., Baker, A., Gallegos, A., and Powis, G. Thioredoxin peroxidase (peroxiredoxin-1) is increased in Thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide and doxorubicin. Arch. Biochem. Biophys., 392: 103-109, 2001
67. Kim, H., Lee, T., Park, E., Suh, J., Park, S., Chung, H., Kwon, O., Ro, Y. K. H., and Shong, M. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J. Biol. Chem., 275: 18266-18270, 2000
68. Sueoka, E., Goto, Y., Sueoka, N., Kai, Y., Kozu, T., and Fujiki, H. Heterogeneous nuclear ribonucleoprotein B1 as a new marker of early detection for human lung cancers. Cancer Res., 59: 1404-1407, 1999
69. Sakaguchi, M., Miyazaki, M., Inoue, Y., Tsuji, T., Kouchi, H., Tanaka, T., Yamada, H., and Namba, M. Relationship between contact inhibition and intranuclear S100C of normal human fibroblasts. J. Cell Biol., 149: 1193-1206, 2000